Бритов А. Н. Агрессивная терапия статинами при остром коронарном синдроме, возможности аторвастатина в суточной дозе 80 мг. Кардиоваскулярная терапия и профилактика. 2009;8(6):82-87.
1. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973; 180: 1332-9.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
3. Шевченко О.П., Мишнев О.Д. Ишемическая болезнь сердца. Монография. Москва “Реафарм” 2005.
4. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ 2000; 324(7353): 1570-6.
5. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A metaregression analysis. JACC 2005; 46(10): 1855-62.
6. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360(9326): 7-22.
7. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005; 366(9493): 1267-78.
8. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14): 1425-35.
9. LaRosa JC, Grundy SM, Kastelein JJ, et al. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targetsstudy). Am J Cardiol 2007; 100(5): 747-52.
10. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294(19): 2437-45.
11. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-9.
12. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Engl J Med 1998; 339(19): 1349-57.
13. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Trial investigators. N Engl J Med 1996; 335(14): 1001-9.
14. Мареев В.Ю., Беленков Ю.Н., Оганов Р.Г., Барбик-Жагар Б. от имени рабочей группы “АТЛАНТИКА”. Аторвастатин в лечении пациентов с ишемической болезнью сердца и дислипидемией и высоким общим риском: оценка эффективности и безопасности. Дизайн и основные результаты исследования АТЛАНТИКА. Кардиология 2008; 11: 4-13.
15. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13(5): 437-52.
16. Seshasai SRK, Ray KK. Intensive Statin Therapy in Coronary Artery Disease: is Lower Cholesterol Better and Safe? Future Cardiol 2009; 5(2): 129-39.
17. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285(13): 1711-8.
18. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495-504.
19. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292(11): 1307-16.
20. Murphy SA, Cannon CP, Wiviott SD, et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy — Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol 2007; 100(7): 1047-51.
21. Nissen SE. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 2004; 292(11): 1365-7.
22. Jacobson TA. Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008; 83(6): 687-700.
23. Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. JACC 2005; 46(8): 1405-10.
24. Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108(13): 1560-6.
25. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. JACC 2006; 48(3): 438-45.
